Wall Street analysts predict that Inspire Medical Systems (NASDAQ:INSP) will report sales of $13.20 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Inspire Medical Systems’ earnings, with the highest sales estimate coming in at $14.10 million and the lowest estimate coming in at $11.60 million. The business is scheduled to announce its next quarterly earnings results on Tuesday, February 5th.
According to Zacks, analysts expect that Inspire Medical Systems will report full year sales of $48.00 million for the current year, with estimates ranging from $47.90 million to $48.10 million. For the next fiscal year, analysts expect that the firm will post sales of $61.80 million, with estimates ranging from $56.60 million to $64.50 million. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for Inspire Medical Systems.
Inspire Medical Systems (NASDAQ:INSP) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.13. The business had revenue of $13.10 million during the quarter, compared to the consensus estimate of $12.86 million. The firm’s quarterly revenue was up 79.9% on a year-over-year basis. During the same period last year, the business posted ($3.42) earnings per share.
Several research analysts recently commented on INSP shares. Zacks Investment Research downgraded shares of Inspire Medical Systems from a “buy” rating to a “hold” rating in a report on Thursday, August 9th. Leerink Swann started coverage on shares of Inspire Medical Systems in a report on Monday, October 29th. They issued an “outperform” rating and a $57.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $40.86.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. lifted its stake in Inspire Medical Systems by 57.3% in the 3rd quarter. Alliancebernstein L.P. now owns 11,800 shares of the company’s stock worth $497,000 after purchasing an additional 4,300 shares in the last quarter. Valeo Financial Advisors LLC purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $229,000. Wasatch Advisors Inc. lifted its stake in Inspire Medical Systems by 17.2% in the 3rd quarter. Wasatch Advisors Inc. now owns 35,006 shares of the company’s stock worth $1,473,000 after purchasing an additional 5,149 shares in the last quarter. Rhumbline Advisers purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $243,000. Finally, Dupont Capital Management Corp purchased a new stake in Inspire Medical Systems in the 3rd quarter worth approximately $314,000.
INSP opened at $46.39 on Friday. Inspire Medical Systems has a 12 month low of $22.50 and a 12 month high of $57.87.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Read More: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.